关于《中国药典》2020年版一些问题的探讨  

Discussion on Some Problems of Chinese Pharmacopoeia 2020 Edition

作　　者：梁惠明[1] 彭敏[1] 杜瓦 LIANG Hui-ming;PENG Min;DU Wa(Jiangmen Institute For Drug Control,Guangdong,Jiangmen 529000,China)

机构地区：[1]江门市药品检验所,广东江门529000

出　　处：《海峡药学》2022年第1期84-86,共3页Strait Pharmaceutical Journal

摘　　要：目的对2020年版药典继续沿用历版药典中存在的某些适用性不强、操作性不强等问题的方法进行探讨。方法列举几例新版药典存在的问题,通过实践试验,进行分析与研究,提出修订建议与同行们商榷。结果与结论希望本文能引起相关部门的重视,为下一步的制修订工作提供参考,使药典标准更加合理化、规范化。OBJECTIVE To discuss the rationality of specific methods used in the 2020 edition of Chinese Pharmacopoeia which was found poor adaptability and operability in the previous editions.METHODS The problems of specific methods used in the new edition of Chinese Pharmacopoeia were listed.Suggestions were put forward to discuss with peers through practical tests and analytical investigation.RESULTS and CONCLUSION We hope that this paper can arouse the attention of relevant departments, and provide reference for the next formulation and revision work to make the pharmacopoeia standard more reasonable and standardized.

关 键 词：中国药典 2020年版 方法 适用性 

分 类 号：R927[医药卫生—药学]